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ABSTRACT
The HIRA histone chaperone complex deposits hi-
stone H3.3 into nucleosomes in a DNA replication-
and sequence-independent manner. As herpesvirus
genomes enter the nucleus as naked DNA, we asked
whether the HIRA chaperone complex affects her-
pesvirus infection. After infection of primary cells
with HSV or CMV, or transient transfection with naked
plasmid DNA, HIRA re-localizes to PML bodies, sites
of cellular anti-viral activity. HIRA co-localizes with
viral genomes, binds to incoming viral and plasmid
DNAs and deposits histone H3.3 onto these. Anti-
viral interferons (IFN) specifically induce HIRA/PML
co-localization at PML nuclear bodies and HIRA re-
cruitment to IFN target genes, although HIRA is not
required for IFN-inducible expression of these genes.
HIRA is, however, required for suppression of viral
gene expression, virus replication and lytic infection
and restricts murine CMV replication in vivo. We pro-
pose that the HIRA chaperone complex represses in-
coming naked viral DNAs through chromatinization
as part of intrinsic cellular immunity.
INTRODUCTION
The HIRA chaperone complex, comprised of HIRA/U
BN1/CABIN1, collaborates with histone binding protein
ASF1a to incorporate H3.3 into chromatin in a DNA
replication-independent manner (1–3). The HIRA complex
is targeted non-specifically to nakedDNAand so is thought
to deposit histone H3.3 through a so-called ‘gap-filling’
function (4). HIRA-mediated H3.3 deposition contributes
to diverse biological functions. The HIRA protein is re-
quired for deposition of histone H3.3 at dynamic chromatin
of active and poised genes and enhancers, polycomb tar-
get genes and sites of DNA damage repair (4–8). Accord-
ingly, HIRA is required for gene activation in some con-
texts (9–11), but also chromatin silencing in others (12,13).
HIRA’s role in H3.3 deposition is thought to underpin di-
verse physiological functions inmetazoans, including sperm
nucleus decondensation after fertilization (3), embryo de-
velopment (5,14,15) and cell senescence and tumor suppres-
sion (16,17).
Cells encounter HIRA’s target––naked, histone-free
DNA––in only special circumstances. Naked DNA is of-
ten a sign of microbial and viral infection (18). Conse-
quently, foreign naked DNA is a trigger for activation of
diverse cellular defense mechanisms, including anti-viral in-
terferon (IFN) and cytokine responses that induce anti-viral
genes and/or enhance the adaptive immune response. Spe-
cificDNA sensors detect microbial, histone-freeDNAs. For
example, in early stages of infection of fibroblasts with her-
pes simplex virus 1 (HSV-1), naked viral DNA enters the
nucleus and is initially sensed by IFI16, which promotes ac-
tivation of IFN and cytokine signaling via STING, NF-kB
and the inflammasome (18). As well as leading to the acti-
vation of anti-viral IFNs and cytokines, naked viral DNAs
also appear to directly activate intrinsic cellular immunity,
a process leading to inhibition of viral gene expression and
replication, potentially caused by heterochromatinization
and silencing of the foreign viral DNA. On infection with
several DNA viruses, this pathway is influenced by the ac-
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tivity of components of subnuclear structures, PML bod-
ies, such as PML and Sp100 and, interestingly, another his-
tone H3.3 chaperone, DAXX (19,20). IFI16 and a number
of other host factors have also been proposed to contribute
to virus heterochromatinization and silencing (21–23).
Given the role of the HIRA chaperone complex in nucle-
osome deposition at naked DNA, and the contribution of
chromatinization of naked viral DNAs to anti-viral immu-
nity, we set out to investigate whether HIRA participates in
intrinsic anti-viral defense.
MATERIALS AND METHODS
Cell culture and IFN treatments
IMR90 cells were obtained from ATCC and were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 20% (v/v) FBS, 2 mM L-Glutamine
and incubated at 37◦C in a humidified 5% CO2 and 3%
O2 atmosphere. HFFs (Diploid human foreskin fibroblasts,
ECACC), U2OS cells (human osteosarcoma, ECACC) and
HEK-293T cells (human embryonic kidney, ECACC) were
propagated in DMEM supplemented with 10% v/v fe-
tal calf serum (FCS, GE Health Care). BHK cells (baby
hamster kidney, ECACC) were grown in Glasgow Modi-
fied Eagle’s Medium containing 10% newborn calf serum
(NCS,GEHealth Care) and 10% tryptose phosphate broth.
HepaRG cells (Human hepatocytes, life Technologies) were
grown in William’s Medium E containing 10% v/v FCS,
2 mM glutamine, 5 g/ml insulin and 0.5 M hydrocor-
tisone. All cell growth media were supplemented with 100
U/ml penicillin and 100 g/ml streptomycin and cells were
incubated at 37◦C in a humidified 5%CO2 and 3%O2 atmo-
sphere. Lentivirus-transduced cells were maintained under
continuous antibiotic selection, as appropriate. Recombi-
nant IFNs were bought from PBL (Human IFN- -11410–
2) and Sigma (IFN--SRP4596 and IFN- -I3265). ELISA
(PBLAssay Science 41410) was performed according to the
manufacturer’s instructions.
Viruses
HCMV strain AD169 (gen bank accession number
FJ527563.1) was propagated in and titrated on HFFs as
described previously (24). Virus was UV-inactivated using
a Stratalinker 1800 (Stratagene) and three bursts of 800uJ
(x100) and stored at −70◦C. HSV-1 strain 17+ and its
derivatives ICP0 null mutant dl1403 and in1318 (25) (gen
bank accession number JN555585.1) were propagated
in BHK cells, infected culture medium was harvested,
cleared from cellular debris by centrifugation and titrated
in U2OS cells, in which ICP0 is not required for efficient
replication of HSV-1. HSV-1 mutant in1318 carries a
temperature-sensitive lesion in ICP4, a deletion of the
ICP0 gene and a mutation within VP16 that inactivates its
ability to stimulate IE gene expression and was propagated
at 31◦C as described previously (26). Viruses in1863 and
dl1403/CMV/lacZ are wild-type (WT) and ICP0-null
(respectively) derivatives of HSV-1 17+ containing the
lacZ gene under control of the HCMV promoter/enhancer
inserted into the tk gene (27).
In vitro virus infections
For co-localization analysis, cells were seeded into 6-well
dishes (with or without coverslips) at 5 × 105 cells per well,
infected the following day with in1318 or UV-HCMV at
multiplicity of infection (MOI) 5 and incubated for 6 days.
For immunofluorescence, cells were seeded at 1 × 105 cells
per well into 24-well dishes on coverslips, infected the next
day with HSV-1 mutant dl1403 at MOI 0.4 and fixed and
stained 24 h post-infection. For plaque assays, cells were
seeded as above and infected the following day with ap-
propriate sequential 3-fold dilutions of WT HSV-1 variant
in1863 and ICP0-null HSV-1 mutant dl1403/CMV/lacZ.
After virus adsorption, cells were overlaid with medium
containing 1% human serum for 24 h and stained for -
galactosidase-positive plaques as described (28). For virus
yield, cells were seeded as above and infected the follow-
ing day at MOI 0.01. At indicated time points post infec-
tion, supernatant was harvested and virus titre determined
by plaque formation assay on U2OS cells as described pre-
viously (29). Forwestern blot analysis, cells were seeded into
24-well dishes at 1 × 105 cells per well, infected at indicated
MOIs and harvested at indicated times post infection. For
ChIP assays, cells were seeded at 3× 106 cells per 15 cm dish
and infected the following daywithUVHCMVor in1318 at
MOI 20. Cells were incubated for 24 h at 37◦C (UVHCMV)
or at the non-permissive temperature of 38.5◦C (in1318).
ChIP
Native ChIP was performed for HIRA and HA-H3.3 as
described previously (17). Antibodies used for ChIP were:
cocktail of mouse mAbs to HIRA (approximately equimo-
lar mixture of WC15, WC19, WC117, WC 119 (30)), HA
(Millipore 05904) (for anti-HA-H3.3 ChIP).MousemAb to
HA tag (Covance, MMS-101R) was used as species/class-
matched negative control Abs. Primer sequences are pro-
vided in Supplementary Table S1.
Generation and production of lentivirus vectors
Hairpins to HIRA and luciferase, and lentivirus vectors ex-
pressing anHA-tagged version of human histone H3.3 have
been described previously (17).
qRT-PCR
Total RNAwas prepared using the RNeasy kit (Qiagen cat-
alog no. 74104), according to the manufacturer’s instruc-
tions. Quantitative reverse transcription-polymerase chain
reaction (qRT-PCR) was performed using the Dynamo
SYBR green kit according to the manufacturer’s instruc-
tions.  Actin was used as housekeeping control.
Western blot
Western blotting was performed as described previously
(17). The following primary antibodies were used for west-
ern blot: mousemAb toHIRA (WC119 (30)), actin (A1978;
Sigma), MAb anti-HCMV-IE1 2470–5604 (AbD Serotec),
HSV1-ICP8 MAb [11E2] ab20194 (Abcam), anti-UL42
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MAb Z1F11 (31), anti-actin rabbit serum A5060 (Sigma-
Aldrich), SV40 T Ag (Santa Cruz sc-147), p53 (Santa Cruz
sc-126), pRb (Cell Signalling Technology 9309S).
Immunofluorescence
Two-color indirect immunofluorescence assays were per-
formed as described previously (32). Primary antibod-
ies used in this study were: cocktail of mouse mAbs to
HIRA (approximately equimolar mixture of WC15, WC19,
WC117, WC 119 (30)), histone H3 (39 163, 1:1000; Active
Motif), promyelocytic leukemia body (anti-PML) (sc-966
and sc5621; Santa Cruz). The secondary antibodies used
were Alexa Fluor 488 conjugated goat anti-mouse (life tech-
nologies, A-11001) and Alexa Fluor 555 donkey anti-rabbit
(life technologies, A-31572). For confocal microscopy sam-
ples were examined using a Zeiss LSM 510 confocal micro-
scope with 488 and 543 nm laser lines, scanning each chan-
nel separately under image capture conditions that elimi-
nated channel overlap. The images were exported as TIFF
files and processed using Adobe Photoshop and Adobe Il-
lustrator.
In vivo experiments
Experiments were performed under the UK Home Of-
fice (project license number PPL 70/8354) guidelines in
line with the EU Directive 2010 and local Ethical Re-
view process (University of Glasgow). The University of
Glasgow ethics committee reviewed and approved the
document and the experiments conducted for this study.
Murine cytomegalovirus (MCMV) infections performed at
Cardiff University were under the UK Home Office license
PPL 30/2969. All lines were maintained on a C57Bl/6J
background. Mice were infected with 3 × 104 PFU sali-
vary gland-propagated Smith strain MCMV via the intra-
peritoneal (i.p) route of administration. Virus stocks and
virus-infected tissue homogenates were titred by plaque as-
say using 3T3 fibroblasts. The alleles used for this studywere
as follows: Hirafl/fl, CAGG-Cre-ER (17). Genotyping was
carried out by Transnetyx (www.transnetyx.com). Recom-
bination by CAGG-Cre-ER was induced with a single i.p.
injection of tamoxifen (80 mg/kg) made up in 10% ethanol
and 90% corn oil, daily for 5 days whenmice were 6–8 weeks
of age. WT mice were CAGG-Cre-ER (n = 8) and HIRA
knockouts were Hirafl/fl, CAGG-Cre-ER (n = 18).
Statistical methods
For pairs of transfections in which experiments were re-
peated three times, we performed the exact Cochran-
Mantel-Haenszel (CMH) test to determine whether or not,
adjusting for experiment, there was a higher proportion of
cells with HIRA localized to PML bodies in one transfec-
tion relative to the other. For every individual experiment
a minimum of 100 cells were counted. The CMH test’s as-
sumption of homogeneity of odds ratios was checked using
Woolf’s test; in cases where this assumption was violated,
Fisher’s exact test was performed on each individual exper-
iment and the largest P-value was selected. All reported P-
values were adjusted using Bonferroni correction.
For secreted IFN- comparison a Mann–Whitney test
was performed. This produced a borderline-significant dif-
ference between the two groups (Mock and pcDNA3), with
a P-value of 0.04953. For affect of knockdown in recruit-
ment of H3 to PML bodies, the data were analyzed using
a t-test. Both comparisons were found to be significant at
the 5% level (Bonferroni-adjusted P-value for shCntrl ver-
sus shH1 was 0.0136; Bonferroni-adjustedP-value for shC-
ntrl versus sh H2 was 0.0499).
Data analysis
Reads were trimmed using Trim Galore (v0.3.0)
(http://www.bioinformatics.babraham.ac.uk/projects/
trim galore/) and quality assessed using FastQC (v0.10.0)
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/).
For RNA-seq analysis paired-end reads are aligned
to the human genome (hg19) using a splicing-aware
aligner (tophat2) (33). Duplicate reads were identified
using the picard tools (1.98) script mark duplicates
(http://picard.sourceforge.net.). Only non-duplicate reads
were retained. See Supplementary Table S1. Reference
splice junctions are provided by a reference transcriptome
(Ensembl build 73), and novel splicing junctions are deter-
mined by detecting reads that span exons that are not in
the reference annotation. Aligned reads are processed to
assemble transcript isoforms, and abundance is estimated
using the maximum likelihood estimate function (cuffdiff)
from which differential expression and splicing can be
derived (34). Genes of significantly changing expression
were defined as FDR corrected P-value < 0.05. Only
ensembl 73 genes of status ‘known’ and biotype ‘coding’
were used for downstream analysis.
To generate heatmaps, first, significantly changing genes
between shLuc 0 and 6 h, and 6 and 24 h of status ‘known’
and biotype ‘coding’ were identified. For each gene the
FPKM value was calculated based on aligned reads, us-
ing Cufflinks (34). Z-scores were generated from FPKMs.
Hierarchical clustering was performed using the R library
heatmap.2 and the distfun = ‘pearson’ and hclustfun = ‘av-
erage’. Principal component analysis (PCA) was performed
using the FPKM values of all ensembl 73 genes of status
‘known’ and biotype ‘coding’. To calculate the proportion
of genes with concordant expression profiles between IFN-
 shLuc and IFN- shHIRA, first all genes which changed
significantly (5%FDR) in expression between shLuc IFN-
0 and 6 h or between shLuc IFN- 6 and 24 h were identi-
fied. Next the genes in the gene set were classified into four
expression profiles––upregulated/upregulated, upregulated
/downregulated, downregulated/downregulated and downr
egulated/upregulated, dependent on the direction of change
in expression from 0 to 6 h and 6 to 24 h respectively. Next,
for the same gene set, the expression profiles were similarly
determined using the shHIRA IFN- datasets. The propor-
tion of genes whereby the profile was concordant between
the IFN- shLuc and IFN- shHIRA datasets was calu-
lated.
For analysis ChIP-seq single-end reads are aligned to
the human genome (hg19) using the Bowtie2 alignment
software (35). Duplicate reads were identified using the
picard tools (1.98) script mark duplicates (http://picard.
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sourceforge.net.). Only unique reads mapping to a single lo-
cation were retained (see Supplementary Table S2). HIRA
binding sites were determined using the USeq package
(v8.6.0) (36). For USeq the window size was 200 bp, the ex-
tension size was 150 bp. To create the enriched regions, the
following parameters were used: -i 2,4 -s 13,1. Input DNA
was used as the normalization control. The ChIP-seq sig-
nal for any given window was calculated as the total num-
ber of fractional reads within a window, divided by the win-
dow length, with the product divided by the total number of
reads in the dataset divided by 1 million. To normalize the
window the ChIP-seq signal of the treatment was divided by
the control signal. Venn diagrams and associated empirical
P-values were generated using the USeq (v7.1.2) tool Inter-
sectLists (36). The −t value used was 22 008, as the total
number of genes of status ‘known’ and biotype ‘coding’ in
ensembl genes 73. The number of iterations used was 1000.
RESULTS
HIRA chromatinizes incoming viral and other foreign DNAs
First, we tested whether HIRA would co-localize to and
interact with histone-free herpesvirus genomes. To prevent
viral proteins from counteracting the cellular anti-viral re-
sponse, cells were infected with UV-inactivated WT hu-
man cytomegalovirus strain AD169 (UVHCMV) or an
HSV type 1 strain expressing a lacZ marker gene (in1318)
and harboring mutations in the viral transactivator pro-
teins ICP0, ICP4 and VP16 which normally counteract
cellular repressors. These viral genomes rapidly enter into
a quiescent, transcriptionally repressed state immediately
upon infection. In human fetal lung fibroblasts (IMR90),
HIRA localized to PML bodies in response to infection
with UVHCMV or HSV in1318 (Figure 1A and B). Con-
sistent with re-localization of HIRA to PML bodies be-
ing, directly or indirectly, a response to naked viral DNA,
transient transfection with purified naked plasmid DNAs,
pcDNA3, pUC or pBSK, also triggered re-localization of
HIRA to PML bodies (Figure 1C and D). Moreover, in
virus-infected or plasmid-transfected cells, HIRA directly
or indirectly bound to the foreign DNA, as measured by
ChIP assay (Figure 1E and F; Supplementary Figure S1A
and B). HIRA’s substrate, histone H3.3, was deposited onto
foreign plasmid DNA and this depended on HIRA (Fig-
ure 1G and H). In sum, we conclude that in cells harboring
foreign transfected plasmid or infected viral DNAs, HIRA
is recruited to PML bodies, proposed sites of anti-viral ac-
tivity. Moreover, HIRA binds to incoming viral and other
foreign DNAs and promotes their chromatinization via de-
position of histone H3.3.
Histone chaperone HIRA responds to interferon
Virus infection is a potent activator of the cellular anti-
viral IFN response (37). Transient transfection with plas-
mid DNA has also been reported to cause secretion of
IFN (38). Therefore, we reasoned that re-localization of
HIRA in plasmid-transfected and virus-infected cells might
be caused, at least in part, by secreted IFN. Indeed, con-
ditioned medium from plasmid-transfected cells contained
increased IFN- (Supplementary Figure S2A), and condi-
tioned medium and purified IFNs were dose-dependent in-
ducers of HIRA’s localization to PML bodies in primary
cells, including in several fibroblast strains and melanocytes
(Figure 2A–D and Supplementary Figure S2B and C). We
and others previously showed that HIRA progressively ac-
cumulates in PML bodies of primary fibroblasts with in-
creasing number of population doublings, and in cells near-
ing or at senescence most cells contained HIRA in PML
bodies as reported previously (16,17,39). However, a panel
of other diverse cell stresses (etoposide, adriamycin, UV
light and ionizing radiation) failed to recruit HIRA to PML
bodies (Figure 2E). Moreover, although IFNs have been re-
ported to induce cellular senescence (40–43), HIRA’s local-
ization to PML bodies in response to IFN was not a con-
sequence of senescence, as this phenomenon also occurred
in IMR90 cells stably expressing SV40 T antigen to disable
the cell senescence program (Supplementary Figure S2D–
F). IFN-stimulated recruitment of HIRA to PML bodies
was not a consequence of increased expression of HIRA,
since there was only a modest change in HIRA expression
at the RNA level and no detectable change at the protein
level (Figure 2F). Interestingly, HIRA’s localization to PML
bodies was impaired in several, but not all, cancer cell lines
(Figure 2G). As in senescent cells, localization of HIRA to
PML bodies was accompanied by similar re-localization of
histone H3 and other members of the chaperone complex,
UBN1 and CABIN1 (Figure 2H and I) (16,17,44,45). We
conclude that in primary cells anti-viral IFNs can trigger re-
localization of the HIRA complex to PML bodies, further
implicating this chaperone complex in the cellular anti-viral
response.
HIRA is not required for activation of IFN target genes
PML bodies have been proposed to facilitate routing of
histones and histone chaperones from the nucleoplasm to
the chromatin (17,39,46,47). Therefore, we reasoned that
HIRA’s recruitment to PML bodies in IFN-treated, virus-
infected and plasmid-transfected cells might, in part, re-
flect its recruitment to IFN-inducible genes and a contribu-
tion to their inducible expression. As shown previously (37),
treatment of primary human fibroblasts with IFN resulted
in widespread time-dependent increases and decreases in
gene expression (Figure 3A, Supplementary Figure S3A
and Table S1). Although canonical IFN target genes were
a small proportion of the total regulated genes, the set of
regulated genes included more than 50% of all such IFN
target genes (Supplementary Figure S3B). To test whether
HIRAmight be involved in control of IFN-regulated genes,
we performed ChIP-seq to determine the distribution of
HIRA across the genome in untreated control cells and cells
treated with IFN for 24 h (Supplementary Table S2). Initial
analysis of selected IFN target genes, such as IFITM1, con-
firmed that increased expression of these genes was often
associated with increased binding of HIRA across the pro-
moter and exons (Supplementary Figure S3C). However,
across all genes there was a relatively poor correlation be-
tween change in expression and change in HIRA binding
after IFN treatment (Spearman Correlation Coefficient =
0.12; Figure 3B). Despite this relatively poor global correla-
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Figure 2. Histone chaperone HIRA responds to IFN. (A) IMR90 cells fluorescently stained with antibodies to HIRA and PML 24 h post-treatment with
2000U/ml of IFN-. (B) Quantitation of cells with HIRA localized to PML bodies from (A) and with cells treated with 2000U/ml each of IFN- and
IFN- . Data are mean ± SEM from three independent experiments, P < 0.05 comparing mock versus IFN-treated cells. (C) Quantitation of cells with
HIRA localized to PML bodies in cells treated with increasing dose of IFN- as indicated. Data are mean ± SEM from three independent experiments, P
< 0.05 as compared to mock for all three doses. (D) Quantitation of cells with HIRA localized to PML bodies in primary cells (IMR90 fibroblasts, MRC5
fibroblasts, WI38 fibroblasts, human epidermal melanocytes (HEM)) treated with and without 2000U/ml of IFN-. Data are mean ± SEM from three
independent experiments, P < 0.05 as compared to its mock treated for each independent cell line. (E) Quantitation of cells with HIRA localized to PML
bodies in cells with indicated triggers and replicative (RS) and oncogene-induced senescent (OIS) cells. Data are mean ± SEM from three independent
experiments, P < 0.05 as compared to its mock treated for RS and OIS, p is non-significant for all other conditions. (F) Left panel: IMR90 cells treated
with 2000U/ml of IFN- and western blotted with indicated antibodies. Right Panel: genome browser representation of mRNA of HIRA in IMR90 cells
treated with and without 2000U/ml of IFN-. (G) Quantitation of cells with HIRA localized to PML bodies in cancer cell lines (A2780, U2OS, RKO,
SAOS2, SW837 and HeLa) treated with and without 2000U/ml of IFN-. Data are mean ± SEM from three independent experiments, P < 0.05 for
A2780, RKO and SW837 cells as compared to their mock treated cells. p is non-significant for all other cell lines. (H) Cells from (A) were fluorescently
labeled with antibodies to HIRA and histone H3. (I) Quantitation of cells with UBN1 and CABIN1 localized to PML bodies in IMR90 cells treated with
and without 2000U/ml of IFN-. Data are mean ± SEM from three independent experiments, P < 0.05 as compared to mock.
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Figure 3. HIRA is not required for activation of IFN target genes. (A–G) IMR90 cells were stably infected with lentivirus-encoded shRNAs to HIRA
(shHIRA) or control (shLuc). Cells were then treated with IFN- either for 6 h or for 24 h as indicated in the legend. (A) Column clustered heatmap of all
differentially expressed genes (FDR≤ 5%) between shLuc 0 and 6 h and/or between shLuc 6 and 24 h. Genes are given by column and samples by row. The
color intensity represents column Z-score (based on FPKM), where red indicates more highly expressed, and blue more lowly expressed genes. (B) Scatter
plot comparing the change in promoter (TSS± 1 kb) HIRA enrichment with change in gene expression after IFN- treatment for 24 h. Genes that change
in expression significantly (FDR ≤ 5%) between shLuc 0 and 24 h are in red. All other genes are in black. HIRA ChIP-seq signals have been normalized
to input control. The gray highlighted section shows genes with an expression fold ≥ 2.5 and HIRA fold ≥ 1 (also in Supplementary Figure S3D). (C)
Box and jitter plots of shLuc 0 and 24 h gene expression (mean FPKM, n = 2) for the genes within the highlighted section of panel B. The P-value was
calculated using aWilcoxon rank-sum test, comparing 0–24 h. The bottom and top of the boxes correspond to the 25th and 75th percentiles respectively, and
the internal band is the median. The plot whiskers correspond to the most extreme value within 1.5 × interquartile range. (D) As 3C, though measuring
HIRA enrichment by ChIP-seq at 0 and 24 h. HIRA ChIP-seq signals have been normalized to input control. (E) Heatmap of the genes in A, ordered as
3A. Samples are HIRA knockdown using an shRNA hairpins (shHIRA). Genes are given by column and samples by row. The color intensity represents
column Z-score (based on FPKM), where red indicates more highly expressed, and blue more lowly expressed genes. The experiment was done in parallel
with shLuc cells in (A); however to simply heatmap, only results from the knockdown cells are shown (shHIRA). Indicated time points refer to hours post
IFN- treatment. (F) Scatter plot of the genes within the highlighted section of (B), comparing shLuc to shHIRA expression. Values are mean FPKMs (n
= 2). The straight-line equation derived from a linear regression is given for both comparisons. Slope of the line indicates no difference between shLuc and
shHIRA. (G) Representative UCSC plot of the OAS1–3 gene cluster, showing expression by RNA-seq (top six tracks) and HIRA enrichment by ChIP-seq
(bottom two tracks). The Y-axis represents library normalized read count. For the gene tracks, introns are given as horizontal lines and exons as vertical
boxes.
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tion, a subset of genes showed amarked positive correlation
between fold change in expression and fold change inHIRA
binding (shaded in Figure 3B and Supplementary Figure
S3D (PCC = 0.62)). At these genes, a marked increase in
HIRA binding was often accompanied by a marked in-
crease in expression, often from a very low level in untreated
cells (Figure 3C andD). These genes weremore than 30-fold
enriched for known up regulated IFN- target genes (Sup-
plementary Figure S3E).
To test whether upregulation of these genes depends
on HIRA, we generated primary human fibroblasts lack-
ing HIRA via lentivirus-encoded shRNA-mediated knock-
down (Figure 1G and Supplementary Figure S3F), and
treated these cells with and without IFN. As shown previ-
ously (17), HIRA knock down blocked overt IFN-induced
recruitment of histone H3 to PML bodies (Supplementary
Figure S3G and H) (although with any partially diffuse
nuclear stain, some co-localization is inevitable and func-
tional significance of this cannot be excluded). However, to
our surprise, RNA-seq analysis showed that knock down
of HIRA had only a very modest effect on global IFN-
induced changes in gene expression (Figure 3E, compare to
Figure 3A). PCA showed that control cells and HIRA defi-
cient cells tended to cluster together (Supplementary Figure
S3I), and∼80%of IFN-regulated genes showed concordant
expression between control cells and HIRA deficient cells
(Supplementary Figure S3J). Most strikingly, knock down
of HIRA had no significant effect even on expression of
those genes that bound HIRA and increased expression af-
ter IFN treatment (Figure 3F). For example, although IFN
target genes OAS1–3 bound HIRA after IFN treatment,
knock down of HIRA had no effect on their IFN inducible
expression (Figure 3G). Based on these data, we conclude
that, while HIRA is recruited following IFN treatment to
many of themost upregulated IFN responsive genes, neither
expression of HIRA nor recruitment of histone H3 to PML
bodies is generally required for activation of these genes.
HIRA is required for efficient suppression of viral infection
These data implicate HIRA in the cellular response to virus
infection and IFN, but do not define a specific anti-viral
function for HIRA. Given that HIRA binds to and chro-
matinizes viral templates (Figure 1), we speculated that
HIRA might directly impact viral DNA replication. To di-
rectly test a role for HIRA in control of viral replication,
we infected control and HIRA-depleted IMR90 cells with
the WT HSV-1 and ICP0-null HSV1 virus dl1403. We ob-
served an increase in virus yield from the infected cells in
absence of HIRA in infection with HSV lacking the viral
transcriptional activator ICP0 (Figure 4A). Furthermore,
knock down of HIRA also led to an earlier onset of the
viral gene expression program in absence of ICP0 (Fig-
ure 4B). Finally, we asked whether HIRA suppressed vi-
ral replication during herpesvirus infection in vivo. For this,
we employed conditional Hira knock out mice (CAGG-Cre-
ER, Hirafl/fl) in which tamoxifen-inducible inactivation of
Hira is directed by a ubiquitously expressed Cre-ER fusion
protein under control of a CAGG promoter (17). Control
(WT, +tamoxifen) or HIRA-deficient (Hirafl/fl, +tamox-
ifen) mice were infected with the −herpesvirus MCMV
and virus load in the spleen was quantified 4 days later.
Western blotting confirmed efficient inactivation of Hira in
the majority of spleens (Figure 4C). Consistent with the in
vitro data this had no consistent effect on expression of IFN
target genes (Figure 4D). However, Hira−/−mice exhibited
a substantially increased viral load in spleen and liver (Fig-
ure 4E and Supplementary Figure S4), reflecting impaired
control of acute MCMV replication. Based on these data,
we conclude that the Hira chaperone complex participates
in anti-viral intrinsic immunity.
DISCUSSION
Here we demonstrate that the HIRA histone chaperone
complex is involved in chromatinization of incoming viral
DNAs and participates in cellular anti-viral intrinsic im-
munity. Several lines of evidence support this view. First,
HIRA relocalizes to PML nuclear bodies in response to in-
coming viral and foreign naked DNAs. PML bodies have
been previously linked to immunological responses to vi-
ral infection (19,20). Second, HIRA binds to incoming viral
and other foreign DNAs and promotes their chromatiniza-
tion by depositing histone H3.3. Third, HIRA responds to
anti-viral IFNs, by localizing to PML nuclear bodies and
to many upregulated IFN responsive genes. Fourth, while
HIRA is not required for IFN inducible gene expression,
we observed an increase in virus yield from infected cells in
absence ofHIRA, after infectionwithHSV lacking the viral
transcriptional activator ICP0. Fifth, viral gene expression
is more efficient in HIRA-depleted cells than control cells,
suggesting an important role for HIRA in cellular anti virus
response. Finally, mice lacking HIRA have a significantly
higher viral load than control mice, suggesting an essential
requirement of HIRA in virus silencing in vivo. Together,
these lines of evidence indicate that HIRA may contribute
to viral gene silencing and thus play a key role in cellular
anti-viral intrinsic immunity.
In apparent contrast to our findings, Placek et al. pre-
viously reported that HIRA activates HSV-1 gene expres-
sion and promotes genome replication, both also linked to
H3.3 deposition (10). Interestingly, however, Placek et al.
performed their studies in HeLa cells. We found that HeLa
cells, and many other transformed human cell lines, fail to
recruit HIRA to PML bodies in response to IFN. This sug-
gests that the anti-viral activity of HIRA may be cell type
specific, and/or that the anti-viral properties of HIRA are
inhibited or counteracted in some cancer cells.
We propose that HIRA’s participation in intrinsic anti-
viral immunity is linked to its previously demonstrated
ability to non-specifically deposit nucleosomes onto naked
DNA via a gap-filling mechanism (4). Other members of
HIRAcomplex,UBN1 andCABIN1 also bind nakedDNA
in a non-specific manner (4). In addition, the HIRA com-
plex likely confers other anti-viral mechanisms, as UBN1
has previously been reported to restrict the productive cycle
of another human herpesvirus, EBV, through binding to the
EBV EB1 protein (48,49). While the alternative H3.3 chap-
erone complex ATRX/DAXX is also involved in anti-viral
intrinsic immunity (28,50–52), ATRX and DAXX do not
bind to naked DNA under the same conditions as HIRA,
UBN1 and CABIN1 (4), suggesting that their anti-viral
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mechanism might be distinct to HIRA. Although histone
H3.3 is often associated with active transcription (53,54),
the HIRA complex and its orthologs, together with histone
H3.3, are also implicated in creating a repressive chromatin
environment (12,13,55,56), likely underlying its anti-viral
function.
In sum, these results, in cell culture and a mouse model,
demonstrate a role of histone chaperone HIRA in sensing
incoming foreign DNAs, suppression of viral gene expres-
sion and productive viral infection both in vitro and in vivo.
We propose that HIRA’s ‘gap filling’ mode of DNA chro-
matinization is targeted to both the host genome for con-
trol of epigenome function and also to foreign DNAs for
suppression of pathogenic infection.
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